UNSPSC 51294904: Ftorpropazine

This classification denotes an antidepressant agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier CU0X85F735. European Medicines Agency schedules Ftorpropazine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07823MIG. Ftorpropazine generally arises in the molecular formula C22H24F3N3O2S.

UNSPSC 51294904 Ftorpropazine, a Commodity code, shows minimal alignment with recent state and local procurement activity. The code nominally identifies a specific pharmaceutical compound, yet the recent solicitations tagged under it actually procure naloxone (an opioid antagonist), generic multi-source pharmaceuticals and over-the-counter products, and direct-to-manufacturer prescription programs—none of which are ftorpropazine. State and local health agencies, cooperative purchasing alliances, and human services commissions are the primary issuing bodies, but the mismatch between the code label and the scope of work being solicited suggests either data-entry error in the tagged opportunities or a classification problem within the source system. The opportunities themselves span naloxone procurement (a narrow, high-specificity buy), broad-based generic pharmaceutical contracting through cooperative purchasing vehicles, and strategic market research into direct-manufacturer prescription fulfillment models.

Geographic activity centers on Florida, Minnesota (via the Minnesota Multistate Cooperative Purchasing Alliance, which includes Oregon and other participating jurisdictions), and Texas. Representative recent opportunities include Seminole County, Florida's IFB60459723LAS (issued June 30, 2026, response due July 26, 2023) for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries; the Minnesota Department of Administration's MMCAP RFP S1070000015802 (due March 26, 2026) for generic multi-source pharmaceuticals and OTC products across state and local facilities; and the Texas Health and Human Services Commission's RFI HHS0017013 (April 3, 2026) exploring vendor capacity for direct-to-manufacturer prescription programs. The code shows little relevant recent activity tied to ftorpropazine specifically and warrants clarification before pursuing opportunities under it.